“Assessment of Patients Affected by Rheumatoid Arthritis Eligible for Biotechnological Agents and Evaluation of Their Healthcare Resource Utilization and Related Costs”. Reumatismo 73, no. 1 (April 19, 2021): 5–14. Accessed June 7, 2025. https://www.reumatismo.org/reuma/article/view/1329.